BACKGROUND:Plasma HIV-1 RNA levels are high in vertically infected infants. Information in older children is limited, particularly in those who have not received antiretroviral therapy. OBJECTIVES: To describe the relationships between HIV-1 RNA, age and CD4 cell count in untreated vertically infected children. DESIGN: HIV-1 RNA was measured in 70 children [median age, 3.5 years (range, 0.4-11.9 years); median CD4 cell count, 881 x 10(6)/l (interquartile range, 576-1347 x 10(6) cells/l)] enrolled in a randomizedplacebo-controlled trial comparing immediate with deferred zidovudinein asymptomatic or mildly symptomatic vertically infected children (PENTA-1 trial). Short-term variability was assessed by comparing HIV-1 RNA at -2 and 0 weeks (prior to randomization). The relationship between age and HIV-1 RNA, and CD4 cell count was analysed using data from all children prior to randomization and sequential samples from 35 remaining on placebo for up to 105 weeks, by fitting mixed linear models. RESULTS: The within-individual SD in viral load was 0.26 log10 copies/ml. The median plasma HIV-1 RNA at enrollment was 4.61 log10 (range, 2.3-6.56 log10 copies/ml), significantly higher in children aged < or = 2 years (median, 5.23 log10 copies/ml) than in those aged > 2 years (4.51 log10 copies/ml; P < 0.0001). Mean HIV-1 RNA fell by 0.38 log10 copies/ml per year up to 2 years of age, by 0.21 log10 copies/ml per year from 2 to 4 years of age, and by 0.03 log10 copies/ml per year from 4 to 6 years of age reaching a nadir of 4.25 log10 copies/ml at 6 years. Mean log10 CD4 cell count declined steadily with age and was not significantly correlated with HIV-1 RNA, although there was some evidence that the rate of log10 CD4 cell decline was negatively correlated with the initial rate of HIV-1 RNA decline. No mutations associated with resistance to zidovudine were observed. CONCLUSIONS: Age is a key factor in the interpretation of both viral load and CD4 cell count in vertically infected children.
RCT Entities:
BACKGROUND: Plasma HIV-1 RNA levels are high in vertically infected infants. Information in older children is limited, particularly in those who have not received antiretroviral therapy. OBJECTIVES: To describe the relationships between HIV-1 RNA, age and CD4 cell count in untreated vertically infected children. DESIGN:HIV-1 RNA was measured in 70 children [median age, 3.5 years (range, 0.4-11.9 years); median CD4 cell count, 881 x 10(6)/l (interquartile range, 576-1347 x 10(6) cells/l)] enrolled in a randomized placebo-controlled trial comparing immediate with deferred zidovudine in asymptomatic or mildly symptomatic vertically infected children (PENTA-1 trial). Short-term variability was assessed by comparing HIV-1 RNA at -2 and 0 weeks (prior to randomization). The relationship between age and HIV-1 RNA, and CD4 cell count was analysed using data from all children prior to randomization and sequential samples from 35 remaining on placebo for up to 105 weeks, by fitting mixed linear models. RESULTS: The within-individual SD in viral load was 0.26 log10 copies/ml. The median plasma HIV-1 RNA at enrollment was 4.61 log10 (range, 2.3-6.56 log10 copies/ml), significantly higher in children aged < or = 2 years (median, 5.23 log10 copies/ml) than in those aged > 2 years (4.51 log10 copies/ml; P < 0.0001). Mean HIV-1 RNA fell by 0.38 log10 copies/ml per year up to 2 years of age, by 0.21 log10 copies/ml per year from 2 to 4 years of age, and by 0.03 log10 copies/ml per year from 4 to 6 years of age reaching a nadir of 4.25 log10 copies/ml at 6 years. Mean log10 CD4 cell count declined steadily with age and was not significantly correlated with HIV-1 RNA, although there was some evidence that the rate of log10 CD4 cell decline was negatively correlated with the initial rate of HIV-1 RNA decline. No mutations associated with resistance to zidovudine were observed. CONCLUSIONS: Age is a key factor in the interpretation of both viral load and CD4 cell count in vertically infected children.
Authors: K Luzuriaga; H Wu; M McManus; P Britto; W Borkowsky; S Burchett; B Smith; L Mofenson; J L Sullivan Journal: J Virol Date: 1999-01 Impact factor: 5.103
Authors: Jane C Lindsey; Michael D Hughes; Avy Violari; Susan H Eshleman; Elaine J Abrams; Mutsa Bwakura-Dangarembizi; Linda Barlow-Mosha; Portia Kamthunzi; Pauline M Sambo; Mark F Cotton; Harry Moultrie; Sandhya Khadse; Werner Schimana; Raziya Bobat; Bonnie Zimmer; Elizabeth Petzold; Lynne M Mofenson; Patrick Jean-Philippe; Paul Palumbo Journal: Pediatr Infect Dis J Date: 2014-08 Impact factor: 2.129
Authors: Hannah Castro; Ali Judd; Diana M Gibb; Karina Butler; Rebecca K Lodwick; Ard van Sighem; Jose T Ramos; Josiane Warsawski; Claire Thorne; Antoni Noguera-Julian; Niels Obel; Dominique Costagliola; Pat A Tookey; Céline Colin; Jesper Kjaer; Jesper Grarup; Genevieve Chene; Andrew Phillips Journal: Lancet Date: 2011-04-20 Impact factor: 79.321
Authors: Ma Isabel de Jose; Santiago Jiménez de Ory; Maria Espiau; Claudia Fortuny; Ma Luisa Navarro; Pere Soler-Palacín; Ma Angeles Muñoz-Fernandez Journal: BMC Infect Dis Date: 2013-01-02 Impact factor: 3.090